Emergent Health (OTCMKTS: EMGE) is moving up steadily in recent trading off its lows under a penny and looks to be under accumulation once again. The stock ran earlier this year to highs over $0.04 but dropped below a penny since then. The Company has been beefing up its management and BOD in recent months bringing on Jim Morrison, the former president of L’Oréal as the new CEO and Son of QVC Founder Joseph Segel, Marvin Segel as Chief Marketing Officer. 

EMGE has been on the acquisition front acquiring Regen Biowellness, Inc., a distributor of various products in the plant-based and regenerative medical fields with an FDA Cleared Immune Booster called ImmunaZin. EMGE also acquired Evolutionary Biologics, Inc., a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. EMGE also has a pending LOI to acquire Fusion Specialty Pharmacies, nationally accredited compounding pharmacies licensed in 27 states and located in St. George, Utah dedicated to formulating creative, individualized, and compounded medications that can improve compliance, maximize the potential for therapeutic success, and reduce the overall cost of healthcare. This acquisition is scheduled to close during this 3rd quarter of 2022.  

Emergent Health (OTCMKTS: EMGE) Curates Companies and Products, Develops and Sells in the Regenerative Health Space … Its products comprise ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. PharmaZu Corp., its newly acquired subsidiary, is a pure play, e-commerce products and service provider focused on The Pet Community, Pet Pharmacy and Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. 

The Company closed some major acquisitions earlier this year including Regen Biowellness, Inc., a distributor of various products in the plant-based and regenerative medical fields. Regen products include Immuniain TM (Immune Booster) – Irreversibly-inactivated pepsinogen fragments for modulating immune function (Immune Booster- FDA Cleared) ImmunaZin contains an FDA approved New Dietary Ingredient (NDI). Regen also makes HydroSoil Fertilizer, a Water retaining Hemp enhanced fertilizer. They also sell an icepack for muscle/joint pain to cool surface and address pain. Patent-pending, FDA pain claim in progress. IcyEase contains menthol, menthol is an approved pain relief ingredient in the FDA’s monograph for topical pain relief. Another product is Micro Voltage Trans Derm C; Patent application in progress for pain with unique and superior absorbing features due to wearer’s movement generated Micro Voltage, and Silverpro – the Company’s FDA approved medical device for the treatment of pain. Revolutionary technology combining genuine silver yarn with low-static carbon fibers, to create the world’s most advanced-compression pain relief fabric. Regen also has 4 different Pending Patent Applications. 

$EMGE With a MC valuation of only $1.2MM, and no dilution in past 3 months, I think this is a great position for what they have going on. They haven't made any recent announcements since several acquisitions were finalized. The plan is clear and I like it, so I bought back in. pic.twitter.com/uQ7AhvfFhg

— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) November 1, 2022

To Find out the inside Scoop on EMGE Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Regen also acquired Evolutionary Biologics, Inc., a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. The purchase price included equity in Emergent and a capital investment into Evolutionary Biologics for sales, scaling of the company operations and promotions. Evolutionary Biologics flagship products include Evo Hybrid which helps jumpstart your body’s own natural healing power to help bring your skin back to youthful suppleness and HydrEyes which helps reduce redness to help reveal your eyes’ natural radiance. 

Evo Hybrid is a proprietary blend of umbilical cord tissue, placental tissue, and amniotic membrane. This product contains the highest quality bioactive biomolecules of Whartons Jelly (MSCs) mesenchymal stem cells and its extracellular matrix. 

HydrEyes, formerly known as Exo Eye is a proprietary blend of Extracellular Vesicle Ophthalmic solution which helps to restore the natural tear’s lipid layer to hold in moisture and reduce tear evaporation helping with dry eye syndrome. 

Evolutionary Biologics’ goal is to create consumer awareness of regenerative medicine with a global presence using science and technology to build products to create external beauty. Evolutionary Biologics intends to use push and pull marketing, social media, and consumer awareness events to create collaborations with clinics for its products. 

On June 29th 2022, Emergent announced its letter of intent to acquire Fusion Specialty Pharmacies, nationally accredited compounding pharmacies licensed in 27 states and located in St. George, Utah dedicated to formulating creative, individualized, and compounded medications that can improve compliance, maximize the potential for therapeutic success, and reduce the overall cost of healthcare. This acquisition is scheduled to close during this 3rd quarter of 2022. 

$EMGE .0066’s —-> .0108 so far, let’s see if it’s got more juice left https://t.co/nz9nv3tvF7 pic.twitter.com/yKoc07mvsK

— aesthetic bull (@t0mmmyf0x) November 2, 2022

For More on EMGE Subscribe Right Now!

Currently trading at a $1.5 million market valuation EMGE OS is 190,851,111 with a public float of just 4 million shares. EMGE is an exciting story developing in small caps; while the Company has some revenues they are virtually debt free. In recent months the Company is in the process of completing 3 major acquisitions including Fusion Specialty Pharmacy which generated $3,801,497 in 2021 Revenues, an approximate 100% increase from 2020 Revenues of $1,971,599. They are also acquiring Revolutionary Biologistics and closed on the acquisition of Regen Biowellness, Inc. a distributor of various products in the plant-based and regenerative medical fields. The Company has also been beefing up its management and BOD in recent months bringing on Jim Morrison, the former president of L’Oréal as the new CEO and Son of QVC Founder Joseph Segel, Marvin Segel as Chief Marketing Officer. Currently EMGE is in the process of auditing its financial statements with the goal of uplisting to fully reporting OTCQB and eventually uplisting to Nasdaq according to management.  Microcapdaily will be covering EMGE so make sure you subscribe to Microcapdaily right now so you don’t miss it. 

Disclosure: we hold no position in EMGE either long or short and we have not been compensated for this article.

The post Emergent Health (OTCMKTS: EMGE) Breaking Out into Copperland as Biotech Closes on Evolutionary Biologics & Regen Biowellness Acquisitions and Audits Filings first appeared on Micro Cap Daily.

Read More